New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-positive Cancer

Alexander Drilon, MD, is a thoracic oncologist and Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, including research focused on ALK-positive cancers. 

Sunday, March 1st at 7:00pm ET, Alexander Drilon, MD joins ALKtALK to present and discuss the latest data on neladalkib (NVL-655). The conversation will include a review of emerging efficacy and safety data, along with discussion of how promising therapies move from clinical trials toward broader patient access. 

The talk will also touch on Dr. Drilon’s ongoing research offering insight into how translational science and biomarker-driven approaches continue to inform treatment strategies. 

Join us live to be informed and empowered by a data-driven conversation focused on where the science is now and where it may be headed next. A live Q&A will follow the presentation, providing attendees with the opportunity to ask questions and engage directly around the data. 

For those unable to attend live, the recording will be available on the ALK Positive YouTube channel. Whether you are newly diagnosed, in treatment, or supporting someone you love, we invite you to join this important ALKtALK and stay connected to the research shaping our community.

#ALKPositive #ALKtALK #LungCancerResearch #MoreResearchMoreTime